Technical Analysis for NBY - NovaBay Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.28 -6.10% -0.02
NBY closed down 6.1 percent on Friday, May 24, 2019, on 38 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical NBY trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Volume Surge Other -6.10%
Wide Bands Range Expansion -6.10%
Oversold Stochastic Weakness -6.10%
New 52 Week Closing Low Bearish -2.57%
Calm After Storm Range Contraction -2.57%

Older signals for NBY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the development of various product candidates for the therapeutic needs of the anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It has categories of compounds, Aganocides and NeutroPhase. The company's Aganocide compounds comprise NVC-422 that is in Phase IIb clinical study for the treatment of adenoviral conjunctivitis, a contagious viral eye infection; impetigo, a highly contagious skin infection; and urinary catheter blockage and encrustation, and associated urinary tract infections. Its NeutroPhase product is a hypochlorous acid solution, has approved for the treatment of patients who suffer from chronic non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. The company has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds, which covers acne, impetigo, and other dermatological conditions. It also has strategic marketing agreement with Pioneer Pharma Co., Ltd. to market its pharmaceutical products in China and other Asian markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Medicine Biotechnology Health California Pharmaceutical Products Catheter Acne Urinary Tract Infections Impetigo
Is NBY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.745
52 Week Low 0.1
Average Volume 558,720
200-Day Moving Average 1.3239
50-Day Moving Average 0.9322
20-Day Moving Average 0.624
10-Day Moving Average 0.389
Average True Range 0.1562
ADX 27.65
+DI 20.7188
-DI 34.1396
Chandelier Exit (Long, 3 ATRs ) 0.7514
Chandelier Exit (Short, 3 ATRs ) 0.6986
Upper Bollinger Band 1.2073
Lower Bollinger Band 0.0407
Percent B (%b) 0.21
BandWidth 186.955128
MACD Line -0.201
MACD Signal Line -0.1793
MACD Histogram -0.0217
Fundamentals Value
Market Cap 4.29 Million
Num Shares 15.3 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -0.35
Price-to-Sales 4.39
Price-to-Book 20.95
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.36
Resistance 3 (R3) 0.36 0.34 0.34
Resistance 2 (R2) 0.34 0.32 0.34 0.34
Resistance 1 (R1) 0.31 0.31 0.30 0.31 0.33
Pivot Point 0.29 0.29 0.29 0.29 0.29
Support 1 (S1) 0.26 0.27 0.25 0.26 0.23
Support 2 (S2) 0.24 0.26 0.24 0.22
Support 3 (S3) 0.21 0.24 0.22
Support 4 (S4) 0.21